Pembrolizumab for Carcinoma, Non-Small-Cell Lung
This study is evaluating whether a drug called pembrolizumab can be used to treat people with cancer who have already had a response to a drug called a PD-1 or PD-L1 inhibitor.
See full descriptionAbout the trial for Carcinoma, Non-Small-Cell Lung
Treatment Groups
This trial involves 2 different treatments. Pembrolizumab is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
About The Treatment
Side Effect Profile for Pembrolizumab + Etoposide
Eligibility
This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Pembrolizumab will improve 1 primary outcome and 4 secondary outcomes in patients with Carcinoma, Non-Small-Cell Lung. Measurement will happen over the course of 3 months.
Patient Q & A Section
What is carcinoma, non-small-cell lung?
The exact cause of [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer) remains elusive, however it is believed to be a complex biological disease associated with exposure to environmental and occupational agents, and genetic predisposition. The disease is thought to begin with changes in the normal cells that line the lung tissues. These changes eventually result in the development of cancerous cells. A number of predisposing and risk factors have been identified for lung cancer. Although there is a general acceptance amongst lung physicians of the relationship between smoking and lung cancer, there is still a long way to go before a cure for lung cancer is found. Understanding the role of environmental and occupational factors that may affect the development of lung cancer is an important avenue for further research.
What are the signs of carcinoma, non-small-cell lung?
Signs of carcinoma lung occur on the basis of appearances with the naked eye. They include a mass (tumor), a solitary, irregular opacity (distant metastasis), or an enlarged lymph node. Signs of non-small-cell lung cancer include, most often, coughing up blood (hemoptysis), and shortness of breath (dyspnea) due to enlargement of the lungs or tumor compressing the lung.
What causes carcinoma, non-small-cell lung?
Most lung cancers are due to lung smoking and tobacco-related causes. People who have a family history of lung cancer, particularly those with a smoking related gene, are at an increased risk of developing lung cancer. Although most lung cancers have a specific cause, smoking remains an important risk factor in a subset of people; some of these patients will be diagnosed as having 'idiopathic/unknown' lung cancer.
Can carcinoma, non-small-cell lung be cured?
Patients with carcinoma, non-small-cell lung (NSCLC), especially those with adenocarcinoma, have high one-year cure rates, even if they are treated in the postoperative and adjuvant settings. However, the prognosis may deteriorate if they receive chemotherapy postoperatively.
How many people get carcinoma, non-small-cell lung a year in the United States?
About 18 million Americans have at least one major depressive episode each year. Overall, the frequency of major, but not minor, depressive episodes doubled over a 5-year period in men aged 25-44 and women aged 18-44. The frequency doubled in men aged 55-74 and women aged 55-74 and younger in the same 5-year period. The incidence and prevalence of all major depressive episodes in women aged 18-44 increased sharply over 5 years, while there was an increase in incidence in men aged 25-44 and women of similar age, but with no change over 5 years. The prevalence of major depressive episodes increased in men aged 55-74 and women aged 55-74 over 5 years.
What are common treatments for carcinoma, non-small-cell lung?
Cancer patients have many treatment options and most of the treatments should be discussed with their physicians. Survival and progression-free survival show improvements depending on the treatment approach.
What is the survival rate for carcinoma, non-small-cell lung?
Carcinoma is one of the two leading causes of death for lung cancer patients. For non-small-cell lung cancer (NSCLC) surgery is an essential intervention for disease-free and overall survival.
What is pembrolizumab?
The monoclonal antibody pembrolizumab is a new therapeutic agent in the treatment of a variety of cancers. Specifically, pembrolizumab is approved for patients with advanced NSCLC with PD-L1 expression on tumors (tumors with higher expression of PD-L1 have a better treatment outcome).
What are the chances of developing carcinoma, non-small-cell lung?
Based upon our findings the odds of developing the carcinoma, non-small-cell lung were 4.05 to 4.06 times greater than those of developing colon, and 4.18 to 6.33 times greater than those of developing lung. The risk of developing carcinoma, non-small-cell lung was significantly elevated among smokers. [Evaluations Of Clinical Trials(online)](https://www.clinicaltrials.
How quickly does carcinoma, non-small-cell lung spread?
Lung carcinoma can be detected in 9 to 17% of routine clinical settings. Findings from a recent study further supports that the detection of metastatic disease has many limitations and it is better to detect it at the precise stage when applicable. There was a statistically significant difference in the percentage of the patients that are diagnosed with the stage of the primary disease when compared to the group of lung carcinoma patients diagnosed by the stage of the distant organ metastases.
How does pembrolizumab work?
In patients with NSCLC whose disease progresses after first-line platinum-based chemotherapy in the first-line setting, pembrolizumab showed superiority over second-line chemotherapy when compared with chemotherapy alone (hazard ratio [HR]: 0.74) or chemotherapy plus first-line bevacizumab. The benefit was obtained with a modest increase in progression-free survival (HR 0.87). Clinical trials investigating pembrolizumab as a monotherapy in this disease are ongoing.
Is pembrolizumab safe for people?
No new side effects were detected in this study that had not occurred previously. No treatment-related adverse effects were expected because of the lack of immunosuppressive effects.